New authorized medicine: VIZIMPRO (dacomitinib)
5 juin 2019
VIZIMPRO (dacomitinib) is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the disease is advanced or has spread. Vizimpro is used on its own and only in patients with certain mutations (changes) in the gene for a protein called epidermal growth factor receptor (EGFR).
Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :